MEDICON VALLEY

LIFE SCIENCES TRADE MISSION

16 November 2016 Denmark Galicia

BIOREGION OF GALICIA (SPAIN)
An opportunity to meet and develop bio business

THE TRADE MISSION

Do you want to meet life sciences companies from the Bioregion of Galicia?

The trade mission organised by BIOGA to Medicon Valley aims to promote relations and meetings between life sciences companies from the Bioregion of Galicia (Spain) and the Danish-Swedish Cluster of life sciences.

Programme

16 November 2016

08.15 Reception and accreditation of participants

08.30 - 8.45 Welcome and presentation of the event

8.45 - 9.30 Presentation of the participating entities

Each participant will have 3 minutes to present themselves. From this moment on a catering service will be available to participants and attendees which will remain open until the end of the individual meetings

9.30 - 12.00 One-to-one meetings

Each participant will have previously closed their meeting agenda. Each meeting will have a maximum duration of 30 minutes

12.00 - 12.30 Closing speech and closure of the day

12.30 - 13.30 Networking lunch

13.30 Possibility of visiting some facilities for companies that wish to do so

PARTICIPATING COMPANIES FROM THE BIOREGION OF GALICIA



🕸) R&D Services

GalChimia

Pharmaceutical research and medical chemistry galchimia.com

Founded in 2001, we have become Spain's leader in synthetic organic chemistry. Our expert, dedicated team of chemists has found a productive outlet for their obsession with chemistry, providing custom synthesis, contract research, process development, and analytical services to clients worldwide. Over the last 14 years we have completed more than 1000 projects in the field of drug discovery and more than 50 projects in the field of process development. Biotechs are entering Phase I studies with products that we helped to shape and API manufacturers supply products using processes we have developed.


MD.USE

Computer simulations of molecular dynamics mduse.com

MD.USE is a global provider of scientific software and computational simulation services. We have experience in the simulation of proteins, standard or synthetic peptides, cyclic or linear oligosaccharides (in particular with cyclodextrins), lipid membranes and membrane proteins, nanopores, carbon nanotubes, graphene, surfactants in the liquid phase or at interfaces and a large variety of heterogeneous molecules.

We also develop and commercialize applications to visualize molecules using modern technologies, such as Virtual Reality, Augmented Reality and 3D-printing.





Oncostellae

Research of new drugs for cancer treatment oncostellae.com

Oncostellae focuses on the discovery of new pharmaceutically active compounds and their development, from its initial phase up to proof of concept in patients (clinical phase IIa). At this stage, we aim to license the results and patents obtained during the project to a consolidated pharmaceutical company for further development.

Our first project is dedicated to the treatment of advanced prostate cancer which, at the moment, is not curable. We have discovered novel antagonists of the androgen receptor that are structurally distinct from current drug chemo types and, therefore, have the potential to offer an improved side-effect profile and overcome drug-induced resistance. AR antagonists are a validated therapeutic option and have a multi-billion dollar market. Recently, a new project on irreversible JAK kinase inhibitors has been started with potential indications in oncology and inflammation. A third project on selective TYK inhibitors will be initiated soon



Hifas da terra

Biotechnology in mycology, food and supplements hifasdaterra.com

Mushrooms stand out for their nutritional and biochemical value to complement and enhance your health and wellbeing. Rich in vitamins, minerals and fatty acids, but also β -glucans, they are an amazing source of health.

We focus on nutrition as the key to improve your wellbeing, whether it is to complement the treatment of certain pathologies or to solve functional disorders.



Lentimed Medical Devices

New materials to soft contact lenses lentimeddev.com

Born as a spin-off of the University of Santiago de Compostela (Spain), Lentimed focuses on the development of a new material suitable for the manufacture of soft contact lenses. The innovation lies in the fact that these lenses incorporate cyclodextrins, a component that allows loading substances in sufficient quantity and transferring them into contact with the tears from the eye in a controlled process.

SPAIN AS A WORLD LEADER IN THE FIELD OF **BIOTECHNOLOGY**

2ND COUNTRY R&D

with more biotechnology companies within the OECD

- + turnover
- + employment

+ investment than in 2014

total increase in turnover

107,788 M€ turnover

7.04% strictly biotech companies

41.40%

generated by companies in which biotechnology is a necessary tool for production

177,973 workers in 2014

+2.91% compared to 2014

51.55%

of the total is attributed to companies that consider biotechnology as a secondary business

ASEBIO 2015 Annual Report

ADVANTAGES OF THE BIOTECH SECTOR IN GALICIA



Talent and research excellence



Business fabric



Modernization and valorisation of traditional sectors



Institutional support programs for the biotech



Entrepreneurial culture



GALICIA AS BIOREGION

Galicia grows twice the state average

2,11% of new companies are biotech, twice the average

3rd autonomous community nationwide with more entrepreneurship in the sector

6th autonomous community nationwide with the largest number of companies using bio

In relation to Spain

4.40% biotech companies are in Galicia

5.10% expenditure on biotech R&D

300 M€ expected turnover in 2020

Galician figures

219

biotech organizations

13.85% of R&D is biotechnological

64.50% internationalization of the sector

+250 M€ current turnover

Galicia is one of the Autonomous Communities in Spain with the most biotechnological potential on both the business and research levels.

The constant transfer of knowledge to businesses comes mainly from the extensive research experience of its 3 universities (A Coruña, Santiago de Compostela and Vigo) with its 2 International Excellence Campuses (Campus Vida and Campus do Mar), as well as from the Public Health System (SERGAS) through the Agency for Health Knowledge (ACIS). Galician academic research is accredited by its position in various international rankings as one of the leaders in terms of scientific production and quality of research.

All this gives Galicia a valuable know-how that has been valorised and transferred to the market in recent years with the establishment of numerous spin-offs that today commercialize the generated research results throughout the world.

The application of biotechnology has managed to increase the percentage of innovation and competitiveness in traditional sectors environmental, maritime, etc.), generating a greater number of companies, more skilled jobs and a higher business volume.

Cebreiro, s/n. 15823 O Pino A Coruña, Galicia. España +34 881 120 459 info@bioga.org www.bioga.org

GALICIA EXPORTS INTERMEDIATE BODIES

Internationalization and external promotion project for the Galician biotechnology sector and its companies which aims to improve their positioning and competitiveness in foreign markets

PROJECT COFINANCED BY



EUROPEAN REGIONAL DEVELOPMENT FUND "A way to make Europe"



